ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1772

Expansion of Autoreactive Unresponsive CD21-/Low B Cells in Sjögren’s Syndrome Associated Lymphoproliferation

David Saadoun1, Benjamin Terrier2, J. Bannock Sr.3, T. Vazquez Sr.4, C. Massad Sr.3, Florence Joly Sr.5, Michelle Rosenzwajg Sr.6, Damien Sene Sr.7, Philippe Benech Sr.5, David Klatzmann Sr.6, Eric Meffre Sr.3 and Patrice Cacoub Sr.8, 1Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, 2Internal Medicine, Cochin University Hospital, Paris, France, 3Department of Immunobiology, Yale University School of Medicine, New Haven, CT, 4I3 “Immunology, Immunopathology, Immunotherapy” laboratory, CNRS UMR 7211 and INSERM U959, Paris, France, 5Prediguard, Marseille, France, 6Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Paris, France, 7Department of Internal Medicine; 5 P3S post-genomic plateform, Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, France, 8Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: B cells and Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: B-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Primary Sjögren’s syndrome (pSS) is the autoimmune disease associated with the higher risk of developing non-Hodgkin lymphoma.

Objective: To determine the nature of B cells driving lymphoproliferation in pSS.

Methods:

B cell subsets and function were analyzed in peripheral blood from 66 adult patients with pSS [including 15 patients with B-cell lymphoproliferative disorder (LPD)] and 30 healthy donors, using flow cytometry, calcium mobilization, and gene array analysis. We tested by ELISA the reactivity of recombinant antibodies isolated from single B cells from pSS-LPD.

Results:

We report here the expansion of an unusual CD21-/low B-cell population which correlates with lymphoproliferation in pSS patients. A majority of CD21−/low B cells from pSS patients expressed autoreactive antibodies, which recognized nuclear and cytoplasmic structures. These B cells belonged to the memory compartment because their immunoglobulin genes were mutated. They were unable to induce calcium flux, become activated, or proliferate in response to B-cell receptor and/or CD40 triggering, suggesting that these autoreactive B cells may be anergic. However, CD21−/low B cells from pSS remained responsive to TLR9 stimulation.  Gene array analyses of CD21−/low B cells revealed molecules specifically expressed in these B cells and that are likely to induce their unresponsive stage.

Conclusion:

pSS patients who display high frequencies of autoreactive and unresponsive CD21-/low B cells are susceptible for developing lymphoproliferation. These cells remain in peripheral blood controlled by functional anergy instead of being eliminated, and chronic antigenic stimulation through TLR stimulation may create a favorable environment for breaking tolerance and activating these cells.


Disclosure:

D. Saadoun,
None;

B. Terrier,
None;

J. Bannock Sr.,
None;

T. Vazquez Sr.,
None;

C. Massad Sr.,
None;

F. Joly Sr.,
None;

M. Rosenzwajg Sr.,
None;

D. Sene Sr.,
None;

P. Benech Sr.,
None;

D. Klatzmann Sr.,
None;

E. Meffre Sr.,
None;

P. Cacoub Sr.,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expansion-of-autoreactive-unresponsive-cd21-low-b-cells-in-sjogrens-syndrome-associated-lymphoproliferation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology